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The acute respiratory distress syndrome (ARDS) is a severe inflammatory disease
manifested as a result of pulmonary and systemic responses to several insults. It is now
well accepted that genetic variation influences these responses. However, little is known
about the genes that are responsible for patient susceptibility and outcome of ARDS.
Methodological flaws are still abundant among genetic association studies with ARDS
and here, we aimed to highlight the quality criteria where the standards have not been
reached, to expose the associated genes to facilitate replication attempts, and to provide
quick-reference guidance for future studies. We conducted a PubMed search from January
2008 to September 2012 for original articles. Studies were considered if a statistically
significant association was declared with either susceptibility or outcomes of all-cause
ARDS. Fourteen criteria were used for evaluation and results were compared to those from
a previous quality assessment report. Significant improvements affecting study design
and statistical analysis were detected. However, major issues such as adjustments for the
underlying population stratification and replication studies remain poorly addressed.
Keywords: genetic susceptibility, acute respiratory distress syndrome, outcome, genetic factors, population
stratification
INTRODUCTION
Acute lung injury (ALI) and its severe form, the acute respiratory
distress syndrome (ARDS), are characterized by acute diffuse lung
inflammation and non-cardiogenic pulmonary edema resulting
from increased capillary-alveolar permeability. While ALI and
ARDS terms continue to be used in the medical literature, their
definition criteria were recently revised, although a consensus
has not been reached (Ranieri et al., 2012; Villar et al., 2013).
New definitions support the categorization of ARDS based on
the hypoxemia severity under mechanical ventilation, as well as
on other physiological and clinical parameters, discouraging the
use of ALI as one of the categories. Hereafter, we will refer to
this constellation of syndromes using the term ARDS, irrespective
of the classification used by the studies reviewed (Bernard et al.,
1994). ARDS shows profound incidence variability across coun-
tries (Rubenfeld et al., 2005; Villar et al., 2013), and it is unknown
whether differences also exist among ethnic groups (Martin et al.,
2003; Erickson et al., 2009; Linko et al., 2009; Villar et al., 2011)
and the extent to which demographic, cultural, economical, and
health system particularities might underlie such differences.
Predisposing genetic factors can interact with the environ-
ment to determine the diversity of clinical manifestations, the
response to treatment and outcomes among ARDS patients
(Cobb and O’Keefe, 2004; Villar et al., 2004; Rahim et al., 2008).
Exposing those genetic factors might reveal therapeutic targets
and a foundation to predict ARDS susceptibility and outcomes.
Association studies have been widely used for detecting common,
low-penetrant, genetic variants that are suggested to contribute to
the genetic architecture of complex diseases (Khoury and Yang,
1998), including ARDS (Flores et al., 2008). For ARDS, these
studies have mostly focused on particular biological candidates
and, only recently, have explored the entire genome (Christie
et al., 2012).We have previously assessed the quality of statistically
significant associations of genetic variants with ARDS from 1996
to 2008 based on major recommendations that support study
robustness (Flores et al., 2008). We hypothesized that, despite
this previous evaluation and the availability of well-known stan-
dard guidelines (Janssens et al., 2011), many association studies in
this field continue to be performed without awareness of minimal
standards and that methodological flaws are still abundant. Here,
we aimed to identify those quality criteria where the standards
have not been reached, to expose the associated candidate genes
to facilitate replication studies, and to create a guidance frame-
work for ongoing and future studies. For that, we have critically
assessed statistically significant candidate-gene associations with
susceptibility or outcome of all-cause ARDS from 2008 to 2012
using 14major quality control criteria, and compared the updated
results with our previous evaluation (Flores et al., 2008).
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MATERIALS AND METHODS
LITERATURE SEARCH
We have previously assessed the quality of genetic association
studies supporting susceptibility and/or outcome in adult ARDS
patients of the period of 1996–2008 (Flores et al., 2008). We have
now conducted a PubMed search from January 2008 to September
2012 by utilizing the same keyword combinations for querying
(“polymorphism” and “acute lung injury,” “polymorphism” and
“ARDS,” and “polymorphism” and “acute respiratory distress syn-
drome”). Because of the plausibility that a fraction of risk variants
for ARDS susceptibility could be also risk factors for outcomes,
both possibilities were jointly analyzed. The retrieved references
were then manually reviewed. Excluding meta-analysis, those
reporting statistically significant associations in adults (p ≤ 0.05)
for any cause of ALI or ARDS irrespective of the type of genetic
variants associated, and published in English, were reviewed by
three of the authors. We are aware that a number of such reported
associations might be false positives. However, this threshold for
significance is preferable over a more conservative strategy at this
stage of field development (Thomas and Clayton, 2004). Finally,
we considered the gene as the unit of replication (Neale and Sham,
2004).
STUDY ASSESSMENT
For simplicity, we focused on the 14 most relevant criteria, pre-
viously utilized by us in Flores et al. (2008), modifying the
exhaustive list provided by Chanock et al. (2007), scoring each
item as present or absent. Chi-squared tests were performed in
SPSS (SPSS Inc., Chicago, IL).
GENE COVERAGE IN GENOTYPING ARRAYS
Gene coverage was calculated with the tagger tool (Barrett et al.,
2005) for SNPs with minor allele frequency >5% in the gene
region captured directly and indirectly by the genome-wide geno-
typing array utilized (with a multi-marker r2 ≥ 0.8).
RESULTS
The PubMed search on the period 2008–2012 allowed a closer
review of 27 original articles reporting statistically signifi-
cant association findings on 31 candidate genes with suscep-
tibility and/or outcomes of all-cause ARDS (Table S1), and
the first genome wide association study (GWAS) for this
syndrome (Christie et al., 2012). The latter was excluded
from the evaluation as its quality control assessment dif-
fers substantially from those applied to candidate-gene stud-
ies. A complementary search querying for the syndrome name
in the HuGeNet Navigator (Yu et al., 2008) gave over-
lapping results, showing studies for additional genes albeit
all reporting statistically non-significant findings. We, there-
fore, continued the quality assessment based on the PubMed
search.
Seventeen studies (63%) provided statistically significant find-
ings with a case-control design and ten (37%) with a cohort.
These were based on a median sample size of 251 cases
[interquartile range (P25–P75): 84–365] and 288 controls (P25–
P75: 190–724) in case-control studies, whereas for cohort studies
the median sample size was 145 patients (P25–P75: 118–215).
In this period, almost all studies (96%) appropriately described
demographical and clinical data for cases and all had an adequate
characterization of the control group (47.1% of them utilized
healthy subjects or population-based controls and 52.9% opted
to use at risk patients as controls). However, only 50% of the
studies explored their power to detect statistically significant
findings.
While roughly a third of studies (35%) focused on a single
variant of the gene under study, the majority (65%) analyzed sev-
eral polymorphisms attaining appropriate gene coverage of com-
mon variation by means of linkage disequilibrium (LD)-based
methods. In most cases (74%), the studies allowed to unambigu-
ously identify the genomic location of the associated variant(s)
on public resources. Similarly, most studies declared that Hardy-
Weinberg equilibrium expectations were assessed (93%), and
that further genotyping error checks were implemented during
the study (59%). Almost half of the studies (48%) stated that
genotyping was performed blind to the disease status of samples.
Focusing on the statistical analyses, 65% of the studies that
needed to control type-I error due to multiple hypothesis testing
did so, and 89% included covariates in the regression analyses.
The magnitude of effects was appropriately reported in terms of
hazard ratios (HRs) or odds ratios (ORs) in almost all reviewed
studies (96%) (Table S1). The adjustment for population stratifi-
cation and replication, in at least an independent study sample,
were declared only in 22 and 19% of the studies, respectively,
two major issues that has not improved over the years (Flores
et al., 2008) (Figure 1). Similarly, almost half of the studies (44%)
pursued the functional significance of associated variants.
On a side-by-side comparison of the two periods reviewed
to date (i.e., 1996–2008 reviewed by Flores et al., 2008 and this
one from 2008 to 2012), significant improvements in the qual-
ity of the published studies were observed in the most recent
period (Figure 1) affecting study design, study reproducibility,
and statistical analysis. These improvements were due to an
increase of studies exploiting the available tools for LD explo-
ration to efficiently select the genetic variants (from 24 to 67%,
chi-squared p = 0.003); controlling type-I error by incorporat-
ing multiple testing adjustments on the analyses (from 10 to 65%,
chi-squared p = 0.0003); and accurately identifying the genomic
location of the associated variant(s) (from 45 to 74%, chi-squared
p = 0.033).
DISCUSSION
We have assessed the evidence obtained during 2008–2012 from
ARDS candidate-gene association studies and compared them
with our previous assessment to objectively evaluate the evolu-
tion of the field, especially in light of the methodology applied
in genetic susceptibility studies. In total, including the evidence
accumulated before 2008 (Flores et al., 2008), 56 studies on 41
candidate genes reported statistically significant associations with
susceptibility or outcomes of all-cause ARDS (Figure 2).
We detected significant improvements affecting the exploita-
tion of resources for LD exploration, the inclusion of multiple
testing adjustments, and the way studies identified the associated
variants by established recommendations. This was also extensi-
ble to sample sizes for case-control designs, as these have roughly
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FIGURE 1 | Histogram comparing quality control scores of association
studies in ARDS published from 1996 to 2008 (taken from Flores et al.,
2008) and from 2008 until present. Statistically significant improvements
affected criteria relevant to study design (LD exploration), study
reproducibility (polymorphism identification) and statistical analysis (multiple
testing adjustments). ∗p-value ≤ 0.05; ∗∗p-value ≤ 0.001.
doubled their median sample by group compared to studies pub-
lished before 2008. Despite this improvement, replications in
independent studies are needed to improve the association reli-
ability. Worth noting, the diversity of samples has increased over
the years, so that across all published studies a few have focused on
African-Americans (6.6%), while the majority continues to use
Europeans (66.7%), East Asians (15%), or multiethnic samples
(11.7%). While all these improvements are stimulating, a down-
side continues to be recognized on the adjustment for population
stratification and replication attempts, as these were conducted in
less than a fifth of all reviewed reports.
The identification of genuine gene associations with ARDS
relies on conducting more replication studies, albeit without sac-
rificing study robustness, as only a few associated genes have been
replicated to date (Figure 2). Among those genes, ACE was asso-
ciated several times and a meta-analysis was recently published
(Matsuda et al., 2012). Although results should be taken with cau-
tion because of power limitations, they revealed variable effects
of an ACE polymorphism with ARDS mortality, present in East
Asians but lacking in Europeans. This illustrates the growing evi-
dence supporting that genetic risks may be population-specific,
either because of gene-gene or gene-environment interactions or
because of frequency effects (Need and Goldstein, 2009). Given
that we are far from having a complete list of ARDS genes, and
that an incomplete overlap of genetic risks between populations
is expected, the study of samples of diverse ancestry should be
encouraged in future studies. It must be noted that across all
reviewed studies, genetic associations with ARDS susceptibility
or outcomes with opposite effects in different ancestry groups
were absent, despite differences by the ARDS triggering insult
have been detected (Christie et al., 2008). One major issue that is
determinant of the robustness of association studies with unre-
lated individuals is the assessment and adjustment of results
for the underlying (sometimes cryptic) population stratification,
which is usually based on data from independent genetic poly-
morphisms (Price et al., 2006). Still today, more than 80% of
the published association studies in ARDS did not apply such an
approach, despite few dozen of very informative genetic variants
(termed AIMs) have demonstrated their utility in specific pop-
ulations (Pino-Yanes et al., 2011; Galanter et al., 2012). As the
studies that focus on particular genomic regions will continue to
be relevant in the field (Chanock et al., 2007), population strati-
fication effects should be minimized in future association studies,
irrespective of the study population being assessed. Therefore, it
becomes essential to develop efficient and straightforward meth-
ods that: (1) could be applied to different populations and be
universally used, and (2) could assist researchers to easily select
a reduced set of AIMs to accurately assess ancestry maintain-
ing affordable costs. Such tools would be useful to validate study
robustness as well as to address the biological differences between
populations, and whether these may trigger disparities in ARDS
susceptibility or outcomes. It must be noted; however, that pop-
ulation stratification also introduces non-genetic effects that will
not be addressed by these methods. It is expected that analyses
of these effects and interactions will bring new opportunities and
challenges in the field (Rotimi and Jorde, 2010).
Establishing the association of genes with ARDS susceptibil-
ity is only the beginning of a process that should continue with
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FIGURE 2 | Diagram showing the official gene symbols for the 41
candidate genes associated with ARDS susceptibility and outcomes,
depicting both chromosome locations and the number of study samples
with statistically significant associations. For each chromosome, lower
arrowheads indicate the location of genes with a single sample association,
and upper arrowheads indicate the location of genes with statistically
significant association findings in at least two study samples. Arrowheads
with asterisk indicate more than one gene in that region. Dots denote that
the gene was replicated in the only GWAS of ARDS published to date.
Underlined gene names indicate that the product has been suggested as a
biomarker for ARDS or its progression in at least one study. ACE, angiotensin
I converting enzyme; ANGPT2, angiopoietin 2; CXCL2, chemokine (C-X-C
motif) ligand 2; DARC, duffy blood group, chemokine receptor; DIO2,
deiodinase, iodothyronine, type II; EGF, epidermal growth factor; F5,
coagulation factor V (proaccelerin, labile factor); FAS, TNF receptor
superfamily, member 6; FTL, ferritin, light polypeptide; GP5, glycoprotein V
(platelet); HMOX1, heme oxygenase 1; HMOX2, heme oxygenase 2; IL6,
interleukin 6; IL10, interleukin 10; IL18, interleukin 18; IL32, interleukin 32;
IRAK3, interleukin-1 receptor-associated kinase 3; LTA, lymphotoxin alpha;
MBL2, mannose-binding lectin 2; MIF, macrophage migration inhibitory
factor; MYLK, myosin light chain kinase; NAMPT, nicotinamide
phosphoribosyltransferase; NFE2L2, nuclear factor (erythroid-derived 2)-like
2; NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells
1; NFKBIA, nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor alpha; NQO1, NAD(P)H dehydrogenase, quinone 1; PI3, peptidase
inhibitor 3; PLAU, plasminogen activator, urokinase; PPARGC1A, peroxisome
proliferator-activated receptor gamma, coactivator 1 alpha; SFTPA1, surfactant
protein A1; SERPINE1, serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1; SFTPA2, surfactant protein A2; SFTPB,
surfactant protein B; SFTPD, surfactant protein D; SOD3, superoxide
dismutase 3; STAT1, signal transducer and activator of transcription 1, 91kDa;
TIRAP, toll-interleukin 1 receptor (TIR) domain containing adaptor protein;
TLR1, toll-like receptor 1; TNF, tumor necrosis factor; TRAF6, TNF
receptor-associated factor 6; VEGFA, vascular endothelial growth factor A.
the discovery of the causal genetic variants. The challenge contin-
ues to be the validation of existing and novel ARDS associations
via robust studies, and future and ongoing studies should amend
the critical issues here recognized. In this effort, new technologies
are allowing a faster field development by means of genome-wide
studies, either using genotyping arrays or exome/whole genome
sequencing. GWAS are as efficient as candidate-gene studies for
detecting weak effect risks, not requiring a previous hypothe-
sis of the biological processes related to the trait. They have
allowed to identify new disease genes never anticipated and led
to new hypothesis and perspectives about disease pathogenesis
(Marchini and Howie, 2010). Despite that, GWAS have major
limitations including high costs, usually impacting on the sam-
ple size, the statistical burden and the gene coverage. In addition,
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most commercial platformsmay offer less coverage for the gene(s)
of interest compared to that achieved in optimal candidate-
gene studies, which can substantially impact study power (Voight
et al., 2012). The first GWAS of ARDS was recently published by
Christie et al. (2012), revealing PPFIA1 as a novel susceptibility
gene involved in cell adhesion and cell-matrix interactions, and
suggesting many others with putative functional roles. This study
also replicated the association of four candidate genes including
IL10, MYLK, ANGPT2, and FAS. This may suggest that all other
candidate gene associations should be considered false discover-
ies. However, one explanation for this inconsistency could be also
the insufficient GWAS coverage of the non-associated candidate
genes (average ≈57%; Table S2). Whatever the case, commercial
platforms will only allow studying a fraction of the millions of
existing genetic variants (Abecasis et al., 2012), and it is antici-
pated that the associations to be revealed will only explain a small
component of the disease (Manolio et al., 2009). Only complete
re-sequencing of individual genomes will guarantee the analysis
of all genetic variation.
Here we have shown that the field still faces several method-
ological challenges, and in the clinical arena there are key issues
to be improved in order to fully understand the genetic pro-
cesses underlying ARDS. Misclassification of phenotypes can
lead to significant reduction in statistical power to detect true
genetic associations, therefore it becomes necessary a better and
more homogeneous patient classification. This could be achieved
by combining the clinical information with different integra-
tive approaches, those based on the determination of the causal
microorganisms by means of metagenomics (Lysholm et al.,
2012) or performing gene expression profiling among patients
(Hu et al., 2012), to name a few. As a proof of concept, in a recent
study by O’Mahony et al. (2012), only when the samples were
restricted to the more severe phenotype, new associations were
revealed and previous findings were replicated. Furthermore,
quantitative phenotypes could be utilized for association testing,
such as ventilator-free days (Kangelaris et al., 2012) or ideally
other traits that are closer to the genotype. This possibility has
been explored in the field with striking (Wurfel et al., 2008) and
replicable results (Pino-Yanes et al., 2010). Additionally, the selec-
tion of the control samples remains a challenge; it is not an easy
task and not a single design is free of bias. The use of either healthy
subjects or at-risk individuals is common among the reviewed
studies. An alternative solution can be the utilization of both types
of controls to reduce selection biases and be able to confidentially
assess the quality of the genotypic data. This strategy has been
used (Song et al., 2010), and will surely reduce the chances that
risk variants reported are causally associated with a confounder
and not with ARDS.
In summary, the methodology for assessing genetic risks in
complex diseases is under development. For ARDS, we conclude
that the main challenge continues to be in providing an analyti-
cally rigorous methodology (adjusting for population stratifica-
tion, relatedness, and technical quality) accompanied by inde-
pendent replication and mechanistic explanations for the results
provided. Still today, the evidence supporting the genetic associ-
ations with ARDS susceptibility or outcomes is at best uncertain,
given the limited statistical power of most studies and the effects
expected for genetic variants involved in complex traits. To guar-
antee proper and high quality studies on genetic susceptibility
and outcomes, we strongly encourage the use of large and well-
defined collection of samples. Consequently, a shift toward the
establishment of international consortia will be necessary.
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